Nephrology for the people: Presidential Address at the 42nd regional meeting of the Japanese society of nephrology in Okinawa 2012

Clinical and Experimental Nephrology

Volumn 17, Issue 4, 2013, Pages 480-487

  Iseki, Kunitoshi ^a  

^a UNIVERSITY HOSPITAL OF THE RYUKYUS   (Japan)

Author keywords

Chronic kidney disease (CKD); End stage kidney disease (ESKD); Predictor; Proteinuria; Survival

Indexed keywords

ALBUMIN; CREATININE;

ALBUMINURIA; ASYMPTOMATIC DISEASE; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; EARLY DIAGNOSIS; EARLY INTERVENTION; GLOMERULUS FILTRATION RATE; HEMATURIA; HUMAN; HYPERTENSION; JAPAN; KIDNEY FAILURE; MASS SCREENING; MEDICAL SOCIETY; MORTALITY; NEPHROLOGY; PATIENT REFERRAL; PREVALENCE; PROPHYLAXIS; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME; URINALYSIS; URINE DIPSTICK;

AGED; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; RENAL DIALYSIS;

EID: 84883267582     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-013-0776-x     Document Type: Review

References (67)

1. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1-S266
2. Nakai S, Iseki K, Itami N, et al. An overview of regular dialysis treatment in Japan (as of December 31, 2010). Ther Apher Dial. 2012.
3. Iseki K. The Okinawa screening program. J Am Soc Nephrol. 2003;14(Suppl 2):S127-30.
4. Iseki K. Screening for renal disease - what can be learned from Okinawa experience. Nephrol Dial Transplant. 2006;21:839-43.
5. Iseki K. Role of chronic kidney disease in cardiovascular disease: are we different from others? Clin Exp Nephrol. 2011;15:450-5.
6. Iseki K, Kinjo K, Kimura Y, et al. Evidence for high risk of cerebral hemorrhage in chronic dialysis patients. Kidney Int. 1993;44:1086-90.
7. Iseki K, Fukiyama K. Predictors of stroke in patients receiving chronic hemodialysis. Kidney Int. 1996;50:1672-5.
8. Iseki K, Kawazoe N, Osawa A, Fukiyama K. Survival analysis of dialysis patients in Okinawa, Japan (1971-1990). Kidney Int. 1993;43:404-9.
9. Iseki K, Kawazoe N, Fukiyama K. Serum albumin is a strong predictor of death in chronic dialysis patients. Kidney Int. 1993;44:115-9.
10. Iseki K, Osawa A, Fukiyama K. Evidence for increased cancer deaths in chronic dialysis patients. Am J Kidney Dis. 1993;22:308-13.
11. Iseki K, Nishime K, Uehara H, et al. Effect of renal diseases and comorbid conditions on survival in chronic dialysis patients. Nephron. 1994;68:80-6.
12. Iseki K, Miyasato F, Tokuyama K, et al. Low diastolic blood pressure, hypoalbuminemia, and risk of death in a cohort of chronic hemodialysis patients. Kidney Int. 1997;51:1212-7.
13. Iseki K, Tozawa M, Yoshi S, Fukiyama K. Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant. 1999;14:1956-60.
14. Iseki K, Fukiyama K, for the Okinawa Dialysis Study Group. Long-term prognosis and incidence of acute myocardial infarction in patients on chronic hemodialysis. Am J Kidney Dis. 2000;36:820-5.
15. Iseki K, Fukiyama K, the Okinawa Dialysis Study (OKIDS) Group. Clinical demographics and long-term prognosis after stroke in patients on chronic hemodialysis. Nephrol Dial Transplant. 2000;15:1808-13.
16. Iseki K, Wakugami K, Maehara A, et al. Long-term survival of chronic dialysis patients in comparison to that of stroke and acute myocardial infarction patients. Clin Exp Nephrol. 2001;5:109-13.
17. Sunagawa H, Iseki K, Uehara H, et al. Improved long-term survival rate of chronic dialysis patients with diabetes Mellitus. Clin Exp Nephrol. 2001;5:168-72.
18. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int. 2002;61:1887-93.
19. Iseki K. Reverse epidemiology in chronic hemodialysis patients. Nephrol Front. 2007;6:82-3.
20. Iseki K, Shinzato T, Nagura Y, Akiba T. Factors influencing long-term survival in patients on chronic dialysis. Clin Exp Nephrol. 2004;8:89-97.
21. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019-32.
22. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetinalfa in chronic kidney disease. N Engl J Med. 2006;355:2085-98.
23. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238-48.
24. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395-407.
25. Iseki K, Tozawa M, Iseki C, Takishita S, Ogawa Y. Demographic trends in the Okinawa Dialysis Study (OKIDS) registry (1971-2000). Kidney Int. 2002;61:668-75.
26. Iseki K, Arima H, Kohagura K, Komiya I, Ueda S, Tokuyama K, Shiohira Y, Uehara H, Toma S. Effects of ARB on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial. Nephrol Dial Transplant. 2013 (in press).
27. Iseki K, Iseki C, Ikemiya Y, Fukiyama K. Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int. 1996;49:800-5.
28. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int. 2003;63:1468-74.
29. Iseki K, Ikemiya Y, Fukiyama K. Blood pressure and risk of end-stage renal disease in a screened cohort. Kidney Int. 1996;49(Suppl 55):S69-71.
30. Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S. Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension. 2003;41:1341-5.
31. Iseki K, Ikemiya Y, Fukiyama K. Predictors of end-stage renal disease and body mass index in a screened cohort. Kidney Int. 1997;52(Suppl 63):S169-70.
32. Iseki K, Ikemiya Y, Fukiyama K. Risk factors of end-stage renal disease and serum creatinine in a community-based mass screening. Kidney Int. 1997;51:850-4.
33. Iseki K, Ikemiya Y, Fukiyama K. Outcome of the screened subjects with elevated serum creatinine in a community-based mass screening. Clin Exp Nephrol. 1998;2:31-7.
34. Iseki K, Oshiro S, Tozawa M, et al. Significance of hyperuricemia on the early detection of renal failure in a cohort of screened subjects. Hypertens Res. 2001;24:691-7.
35. Iseki K, Ikemiya Y, Inoue T, et al. Significance of hyperuricemia as a risk factor of developing ESRD in a screened cohort. Am J Kidney Dis. 2004;44:642-50.
36. Iseki K, Ikemiya Y, Iseki C, Takishita S. Hematocrit and the risk of developing end-stage renal disease. Nephrol Dial Transplant. 2003;18:899-905.
37. Tozawa M, Iseki K, Iseki C, et al. Influence of smoking and obesity on the development of proteinuria. Kidney Int. 2002;62:956-62.
38. Iseki K, Ikemiya Y, Kinjo K, et al. Prevalence of high fasting plasma glucose and risk of developing end-stage renal disease in a screened cohort. Clin Exp Nephrol. 2004;8:250-6.
39. Tozawa M, Iseki K, Iseki C, et al. Triglyceride, but not total cholesterol or low-density lipoprotein cholesterol, levels predicts development of proteinuria. Kidney Int. 2002;62:1743-9.
40. Tanaka H, Shiohira Y, Uezu Y, et al. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int. 2006;69:369-74.
41. Iseki K. Factors influencing development of end-stage renal disease. Clin Exp Nephrol. 2005;9:5-14.
42. Vivante A, Afek A, Frenkel-Nir Y, et al. Persistent asymptomatic isolated microscopic hematuria in Israeli adolescents and young adults and risk for end-stage renal disease. JAMA. 2011;306(7):729-36.
43. Iseki K. Evidence for asymptomatic microhematuria as a risk factor for the development of ESRD. Am J Kidney Dis. 2012;60:12-4.
44. Iseki K, Shoji T, Nakai S, et al. Higher survival rates of chronic hemodialysis patients on antihypertensive drugs. Nephron Clin Pract. 2009;113:C183-90.
45. Robinson BM, Port FK. International hemodialysis patient outcomes comparison revisited: the role of practice patterns and other factors. CJASN. 2009;4:S12-7.
46. Cooper BA, Branley P, Bulfone L, et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med. 2010;363:609-19.
47. Rosansky SJ, Eggers P, Jackson K, et al. Early start of hemodialysis may be harmful. Arch Int Med. 2011;171:396-403.
48. Yamagata K, Nakai S, Masakane I, et al. Ideal timing and predialysis nephrology care duration for dialysis initiation; from analysis of Japanese Dialysis initiation survey. Ther Apher Dial. 2012;16:54-62.
49. Yamagata K, Nakai S, Iseki K, et al. Late dialysis start did not affect long-term outcome in Japanese dialysis patients: long-term prognosis from Japanese Society of Dialysis Therapy Registry. Ther Apher Dial. 2012;16:111-20.
50. Japanese Society of Nephrology. Clinical practice guidebook for diagnosis and treatment of chronic kidney disease. Tokyo: Tokyo Igakusha; 2012.
51. Japanese Society of Nephrology. Evidence-based practice guideline for the treatment of CKD. Tokyo: Tokyo Igakusha; 2009.
52. Yamagata K, Makino H, Akizawa T, et al. Design and methods of a strategic outcome study for chronic kidney disease - frontier of renal outcome modifications in Japan (FROM-J). Clin Exp Nephrol. 2010;14:144-51.
53. Iseki K, Asahi K, Moriyama T, et al. Risk factor profiles based on eGFR and dipstick proteinuria: analysis of the participants of the Specific Health Check and Guidance System in Japan 2008. Clin Exp Nephrol. 2012;16:244-9.
54. Sugiyama H, Yokoyama H, Sato H, et al. Japan Renal Biopsy Registry: the first nationwide, web-based, and prospective registry system of renal biopsies in Japan. Clin Exp Nephrol. 2011;15(4):493-503.
55. Yokoyama H, Sugiyama H, Sato H, et al. Renal disease in the elderly and the very elderly Japanese: analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol. 2012;16:903-20.
56. Levey A, de Jong PE, Coresh J, et al. Chronic kidney disease - definition, classification and prognosis: a KDIGO controversies conference report. Kidney Int. 2011;80:17-28.
57. Van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79:1341-52.
58. Gansevoort RT, Matsushita K, van der Velde M, et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int. 2011;80:93-104.
59. Astor BC, Matsushita K, Gansevoort RT, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011;79:1331-40.
60. Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379:165-80.
61. Matsushita K, Mahmoodi BK, Woodward M, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA. 2012;307:1941-51.
62. Hallan SI, Matsushita K, Sang Y, et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA. 2012;308:2349-60.
63. Mahmoodi BK, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet. 2012;380:1649-61.
64. Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012;380:1662-73.
65. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013
66. Imai E. The coming age of geriatric nephrology. Clin Exp Nephrol (Epub Nov 8, 2012)
67. Li L, Astor BC, Lewis J, et al. Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis. 2012;59:504-12.